ArticleExperimental brain research2025
The link between eye movements and cognitive function in mild to moderate Alzheimer's disease.
Article in Experimental brain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Exploring Alzheimer Disease from a Retinal and Ocular Perspective.Biomedicines · 2026Review
- Eye tracking as a digital biomarker in neurodegenerative diseases.Journal of neurology · 2026Review
- Visual Function in Alzheimer's Disease: Current Understanding and Potential Mechanisms Behind Visual Impairment.Journal of clinical medicine · 2025Review
- Eye movement abnormalities in Alzheimer's disease and other neurodegenerative dementias: insights from current evidence and priorities for future research.Frontiers in ophthalmology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study investigated the relationship between eye movement parameters and cognitive function in patients with mild to moderate Alzheimer's disease (AD). A total of 80 patients with AD (mild and moderate) and 34 normal controls (NC) participated. Neuropsychological assessments were conducted using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), while eye movements were recorded using eye-tracking technology. Comparisons of neuropsychological scores and eye movement parameters were made across the groups, and partial correlation analysis was performed to examine associations between eye movement metrics and specific cognitive domains. No significant differences were found among the groups in pursuit and fixation tasks. However, in pro-saccade tasks, patients in the moderate AD group exhibited significantly lower accuracy and longer latency compared to those in the mild AD and NC groups. Similarly, in anti-saccade tasks, the moderate AD group showed significantly lower accuracy and error correction rates compared to the other groups. Partial correlation analysis revealed that overall cognitive function was positively associated with the accuracy of pro-saccade and anti-saccade tasks, as well as the error correction rate of anti-saccade tasks, but negatively associated with pro-saccade latency. Further, orientation was negatively correlated with saccade latency and positively correlated with saccade accuracy, while visuospatial skills were positively associated with the accuracy of both saccade and anti-saccade tasks. A positive correlation was also observed between word fluency and both saccade accuracy and error correction rate. These findings indicate that eye movement parameters, particularly those related to saccade and anti-saccade tasks, are associated with various cognitive domains in mild to moderate AD patients. Eye-tracking technology may provide a convenient and non-invasive tool for assessing cognitive function and aiding in the diagnosis and evaluation of AD.
Indexed as
Identifiers
39754620What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.